



DAPTOMYCIN: A DRUG UTILIZATION REVIEW AT A GENERAL HOSPITAL


E.M. martin gozalo1, L. prieto borja2, G. Toledano Mayoral1, M.A. arias moya1, M. hernandez segurado1, M. bonilla porras1, E. castillo bazan1, J. becares martinez1, M. gomez perez1, M.I. panadero esteban1, B. rodriguez vargas1.

1Hospital Universitario Fundación Jimenez Diaz, pharmacy, madrid, Spain.

2Hospital Universitario Fundación Jimenez Diaz, microbiology, madrid, Spain.

Purpose: To check the adequacy of daptomycin against the indications licensed in product information and also against Treatment Guidelines consensuses from different medical societies.

Material and methods: Retrospective observational study. We studied patients treated with daptomycin (January 2012 – December 2012) at a general hospital in its different units. Information was obtained from the Pharmacy's Service register, patient's history and Microbiology's database.



	INTENSIVE UNIT CARE	OTHER UNITS
EMPIRICAL TREATMENT	90 %	86 % (4 patients blood cultures were not requested)
DAPTOMYCIN SENTITIVE MICROORGANISMS	Isolated in 20 % of blood cultures	Isolated in 36 % of blood cultures
NEGATIVE SAMPLES OR NON SUSCEPTIIBLE MICROORGANISMS	80 %	64 %
VANCOMYCIN MIC	Requested in 4 patients 4: CMI< 0,5 → O treated with vancomycin	Requested in 11 patients (4 previously treated with it) 7: CMI < 1 → 0 treated with vancomycin

Conclusion:

Treatment is essentially empirical, treatment guidelines of infections caused by SA are not followed.

It is recommended to treat the patient with daptomycin if vancomycin MIC is> 1.5 or if patients have previously been treated with it.